Feasibility of Predicting MCIAD Using Neuropsychological Tests and Serum β-Amyloid

Abstract EN

We examined the usefulness of brief neuropsychological tests and serum Aβ as a predictive test for detecting MCI/AD in older adults.

Serum Aβ levels were measured from 208 subjects who were cognitively normal at enrollment and blood draw.

Twenty-eight of the subjects subsequently developed MCI (n=18) or AD (n=10) over the follow-up period.

Baseline measures of global cognition, memory, language fluency, and serum Aβ1–42 and the ratio of serum Aβ1–42/Aβ1–40 were significant predictors for future MCI/AD using Cox regression with demographic variables, APOE ε4, vascular risk factors, and specific medication as covariates.

An optimal sensitivity of 85.2% and specificity of 86.5% for predicting MCI/AD was achieved using ROC analyses.

Brief neuropsychological tests and measurements of Aβ1–42 obtained via blood warrants further study as a practical and cost effective method for wide-scale screening for identifying older adults who may be at-risk for pathological cognitive decline.